Coronavirus Update: US FDA Panel To Review J&J’s Vaccine On 26 February

Plus: Daiichi Signs Japan Deal With AZ

05 Feb 2021

• By Scrip Team

Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.

J&J Covid vaccine — J&J's vaccine, named Ad26.COV2.S, could gain an emergency use authorization on 26 February.

Johnson & Johnson has applied to the US Food and Drug Administration for emergency use authorization for its COVID-19 vaccine, which will be reviewed by an expert panel on Friday 26 February.

If authorized, Johnson & Johnson's adenovirus-based vaccine will be the third approved in the US, joining the mRNA-based vaccines from Moderna, Inc